HPLW is a Vascular Endothelial Growth Factor (VEGF)-mimicking beta-hairpin peptide endowed of proangiogenic effect and showing valuable biomedical application in the proangiogenic therapy. However, the translational potential of HPLW is limited by its low metabolic stability, which would shorten the in vivo efficacy of the molecule. Here, we developed a peptide analog of HPLW, named HPLW2, that retains the structural and biological properties of the original peptide but features an impressive resistance to degradation by human serum proteases. HPLW2 was obtained by covalently modifying the chemical structure of the peptide with molecular tools known to impart protease resistance. Notably, the peptide was cyclized by installing an interstrand triazole bridge through Cu(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) reaction. HPLW2 appears as a novel and promising drug candidate with potential biomedical application in the proangiogenic therapy as a low molecular weight drug, alternative to the use of VEGF. Our work points out the utility of the interstrand triazole bridge as effective chemical platform for the conformational and metabolic stabilization of beta-hairpin bioactive peptides.

Metabolic and conformational stabilization of a VEGF-mimetic beta-hairpin peptide by click-chemistry

De Rosa, Lucia
Primo
;
Diana, Donatella;Di Stasi, Rossella;D'Andrea, Luca Domenico
Ultimo
2021

Abstract

HPLW is a Vascular Endothelial Growth Factor (VEGF)-mimicking beta-hairpin peptide endowed of proangiogenic effect and showing valuable biomedical application in the proangiogenic therapy. However, the translational potential of HPLW is limited by its low metabolic stability, which would shorten the in vivo efficacy of the molecule. Here, we developed a peptide analog of HPLW, named HPLW2, that retains the structural and biological properties of the original peptide but features an impressive resistance to degradation by human serum proteases. HPLW2 was obtained by covalently modifying the chemical structure of the peptide with molecular tools known to impart protease resistance. Notably, the peptide was cyclized by installing an interstrand triazole bridge through Cu(I)-catalyzed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) reaction. HPLW2 appears as a novel and promising drug candidate with potential biomedical application in the proangiogenic therapy as a low molecular weight drug, alternative to the use of VEGF. Our work points out the utility of the interstrand triazole bridge as effective chemical platform for the conformational and metabolic stabilization of beta-hairpin bioactive peptides.
2021
Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" - SCITEC
Istituto di Biostrutture e Bioimmagini - IBB - Sede Napoli
Click-chemistry
Proangiogenic peptide
Protease resistance
Triazole
β-hairpin
CuAAC
File in questo prodotto:
File Dimensione Formato  
Eur J Med Chem 2021.pdf

solo utenti autorizzati

Descrizione: File pdf
Tipologia: Versione Editoriale (PDF)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.28 MB
Formato Adobe PDF
1.28 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
De Rosa et al_EJMC_postprint.pdf

Open Access dal 27/05/2023

Descrizione: versione accettata dell'articolo
Tipologia: Documento in Post-print
Licenza: Creative commons
Dimensione 767.26 kB
Formato Adobe PDF
767.26 kB Adobe PDF Visualizza/Apri
DeRosa et al Supplementary data_REVISED_final.pdf

accesso aperto

Descrizione: supplementary data
Tipologia: Altro materiale allegato
Licenza: Altro tipo di licenza
Dimensione 527.3 kB
Formato Adobe PDF
527.3 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.14243/476241
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact